The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs

Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development

Volumn , Issue , 2006, Pages 1-13

  Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Biotech drugs; Drug development; Pharmaceutical industry; Pharmacodynamics; Pharmacokinetics; Regulatory guidance

Indexed keywords

EID: 84889826166     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527609628.ch1     Document Type: Chapter

References (25)

1. Pharmaceutical Research and Manufacturers of America. 2004. Medicines in Development - Biotechnology - Survey. Washington, DC.
2. Arlington, S., S. Barnett, S. Hughes, and J. Palo. 2002. Pharma 2010: The Threshold to Innovation. IBM Business Consulting Services, Somers, NY.
3. Berg, C., R. Nassr, and K. Pang. 2002. The evolution of biotech. Nat. Rev. Drug Discov. 1: 845-846.
4. Meibohm, B., and H. Derendorf. 1997. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int. J. Clin. Pharmacol. Ther. 35 : 401-413.
5. Derendorf, H., and B. Meibohm. 1999. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm. Res. 16 : 176-185.
6. Holford, N.H., and L.B. Sheiner. 1982. Kinetics of pharmacologic response. Pharmacol. Ther. 16 : 143-166.
7. Curtis, G., W. Colburn, G. Heath, T. Lenehan, and T. Kotschwar. 2000. Faster Drug Development. Appl. Clin. Trials 9 : 52-55.
8. Sheiner, L.B., and J. Wakefield. 1999. Population modelling in drug development. Stat. Methods Med. Res. 8 : 183-193.
9. Sheiner, L.B. 1997. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61: 275-291.
10. Meibohm, B., and H. Derendorf. 2002. Pharmacokinetic/pharmacodynamic studies in drug product development. J. Pharm. Sci. 91: 18-31.
11. Steimer, J.L., M.E. Ebelin, and J. Van Bree. 1993. Pharmacokinetic and pharmacodynamic data and models in clinical trials. Eur. J. Drug Metab. Pharmacokinet. 18 : 61-76.
12. Sheiner, L.B., and J.L. Steimer. 2000. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. Toxicol. 40 : 67-95.
13. Peck, C.C., W.H. Barr, L.Z. Benet, J. Collins, R.E. Desjardins, D.E. Furst, J.G. Harter, G. Levy, T. Ludden, J.H. Rodman, et al. 1994. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J. Clin. Pharmacol. 34 : 111-119.
14. Machado, S.G., R. Miller, and C. Hu. 1999. A regulatory perspective on pharmacokinetic/pharmacodynamic modelling. Stat. Methods Med. Res. 8 : 217-245.
15. Lesko, L.J., M. Rowland, C.C. Peck, and T.F. Blaschke. 2000. Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans. J. Clin. Pharmacol. 40 : 803-814.
16. Breimer, D.D., and M. Danhof. 1997. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The 'wooden shoe' paradigm. Clin. Pharmacokinet. 32 : 259-267.
17. Tang, L., A.M. Persky, G. Hochhaus, and B. Meibohm. 2004. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 93 : 2184-2204.
18. Levy, G. 1994. Pharmacologic targetmediated drug disposition. Clin. Pharmacol. Ther. 56 : 248-252.
19. Nagle, T., C. Berg, R. Nassr, and K. Pang. 2003. The further evolution of biotech. Nat. Rev. Drug Discov. 2 : 75-79.
20. CDER/FDA. 2003. Exposure Response Relationships: Guidance for Industry. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville.
21. International Conference on Harmonization. 1994. ICH E4 - Dose-Response Information to Support Drug Registration. European Agency for the Evaluation of Medicinal Products, London.
22. International Conference on Harmonization. 1997. ICH S6 - Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. European Agency for the Evaluation of Medicinal Products, London.
23. Reichert, J., and A. Pavolu. 2004. Monoclonal antibodies market. Nat. Rev. Drug Discov. 3 : 383-384.
24. Griffiths, S. 2004. Betting on biogenerics. Nat. Rev. Drug Discov. 3 : 197-198.
25. EMEA. 2005. Guideline on Similar Biological Medicinal Products. European Agency for the Evaluation of Medicinal Products, London.